PhD, MBA, Chair of the Scientific Board
Dr. Justin Grant has over 15 years experience in leading pharmaceutical research in sustained drug release formulations. He held academic appointments at the University of Toronto’s Faculty of Pharmacy and UHN’s Techna Institute for the Advancement of Technology for Health. For over 10 years, he has managed a $50M preclinical cancer research facility (the STTARR Innovation centre) at Princess Margaret Cancer Centre. Justin is currently the Chair of the Scientific Advisory Board for Avicanna.
Dr. Christine Allen
Christine Allen is a Professor and the GlaxoSmithKline Chair in Pharmaceutics and Drug Delivery in the Leslie Dan Faculty of Pharmacy at the University of Toronto. Dr. Allen’s research is focused on the design and development of new materials and technologies for the delivery of drugs and contrast agents in addition to Synthesis of new polymer materials for nanotechnology-based drug delivery. Her research has resulted in over 120 peer-reviewed publications on both lipid and polymer-based drug delivery approaches.
Dr. Amza Ali
MD, MSc, FRCP, FACP, FAAN, MBA
Dr. Ali trained in neurology in the UK and in New York. His work to advance epilepsy care in the Caribbean has received international recognition. He holds an MBA from the Rotman School of Management, University of Toronto. The development of a sustainability model in his current doctoral program at the UK’s Henley Business School drives his interest in new pharmacological solutions for epilepsy and other neurological conditions. He is a Fellow of the American Epilepsy Society.
Dr Hance Clarke
MD, FRCP, PhD
Dr. Clarke is currently the Director of Pain Services and the Medical Director of the Pain Research Unit at the Toronto General Hospital. He is recognized internationally for his research on novel Transitional Pain Programs, novel acute pain treatment and identifying risk factors associated to opioid use. He is well regarded as one of the top international clinicians researching the efficacy of cannabinoids in pain management. Over the past five years he has authored 47 peer reviewed manuscripts.
Dr. Chandra Panchal
Dr. Panchal is the CEO of Axcelon Biopolymers, has authored over 70 scientific papers, has several patents in oncology, diagnostics, biopolymers and microbiology, and is a Professor in chemical and biochemical engineering at the Western University. He currently sits on the boards of Medicenna Therapeutics (MDNA) an oncology company and Canadian Oil Recovery and Remediation Inc (CVR). Dr. Panchal obtained a M.Sc. in molecular biology and a PhD in biochemical engineering from the University of Western Ontario.
Dr. Saeid Babaei
Dr. Babaei brings over 20 years of research and executive experience to Avicanna. He led several novel and first-in-class product opportunities to either commercialization or to late-stage development. Dr. Babaei brings a tremendous business foresight having closed over 15 licensing and strategic alliance transactions, as well as raising over $50 million in equity financing. He is currently President & CEO of AbCelex Technologies and Chairman of two TSX-V listed clinical stage immuno-oncology companies.
Dr. Nimish N. Purohit
B.Sc., MBBS, DPM (Dublin, Ireland), MRCPsych (U.K.), FRANZCP, FRCPC
Dr. Purohit is the former Chief of Psychiatry at Joseph Brant Memorial Hospital (Burlington, Ontario) and an Assistant Clinical Professor (Adjunct) at McMaster Unversity. He practices as a consultant psychiatrist in his private practice and the Ontario Tele-Health Network. Dr. Purohit is a lead consultant in three methadone clinics in the Hamilton Region and the Principal and Chief Consultant at a medical clinic specializing in the use and research of medical cannabis for a range of illnesses.